Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis
Background: Regorafenib (REG) is an oral multikinase inhibitor used in colorectal cancer, gastrointestinal stromal tumour and hepatocellular carcinoma. Several adverse events (AEs) are commonly reported during REG administration, and strategies for managing AEs in everyday clinical practice include...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-07-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758835920936932 |
id |
doaj-09f9f8ae0b1749e19c6d31b7f5acb14d |
---|---|
record_format |
Article |
spelling |
doaj-09f9f8ae0b1749e19c6d31b7f5acb14d2020-11-25T02:42:14ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592020-07-011210.1177/1758835920936932Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysisAlessandro RizzoMargherita NanniniMarco NovelliAngela Dalia RicciValerio Di ScioscioMaria Abbondanza PantaleoBackground: Regorafenib (REG) is an oral multikinase inhibitor used in colorectal cancer, gastrointestinal stromal tumour and hepatocellular carcinoma. Several adverse events (AEs) are commonly reported during REG administration, and strategies for managing AEs in everyday clinical practice include supportive care, dose modifications and, when necessary, treatment withdrawal. We performed a systematic review and meta-analysis to assess the schedule treatment modifications of REG associated with AEs across randomized controlled clinical trials (RCTs). Methods: Eligible studies included RCTs assessing standard dose REG versus placebo. Outcomes of interest included: AE-related permanent discontinuation, dose interruptions and dose reductions. Results: We retrieved all the relevant RCTs through PubMed/Med, Cochrane library and EMBASE: 7 eligible studies involving a total of 2099 patients (Regorafenib: 1362; placebo: 737) were included in our analysis. The use of REG was associated with higher incidence and risk of all outcomes of interest when compared with placebo. The incidences of permanent discontinuation, dose interruptions and dose reductions in patients receiving REG were 9.7%, 57.2% and 47%, respectively, versus 3.3%, 16.7% and 7.7% of placebo group; compared with placebo, the summary relative risks (RRs) of permanent discontinuation, dose interruptions and dose reductions in REG arm were 2.80 (95% CI 1.85–4.22), 3.21 (95% CI 2.59–3.99) and 6.02 (95% CI 3.28–11.03), respectively. Conclusions: Treatment with REG at the standard dose of 160 mg is associated with a significant increase in AE-related permanent discontinuation, dose interruptions and dose reductions. Prompt identification and management of AEs seem mandatory to obtain maximal benefit from REG treatment. In the current landscape, dose personalization of REG may have the potential to improve quality of life, minimize treatment discontinuation and maximize patient outcomes.https://doi.org/10.1177/1758835920936932 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alessandro Rizzo Margherita Nannini Marco Novelli Angela Dalia Ricci Valerio Di Scioscio Maria Abbondanza Pantaleo |
spellingShingle |
Alessandro Rizzo Margherita Nannini Marco Novelli Angela Dalia Ricci Valerio Di Scioscio Maria Abbondanza Pantaleo Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis Therapeutic Advances in Medical Oncology |
author_facet |
Alessandro Rizzo Margherita Nannini Marco Novelli Angela Dalia Ricci Valerio Di Scioscio Maria Abbondanza Pantaleo |
author_sort |
Alessandro Rizzo |
title |
Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis |
title_short |
Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis |
title_full |
Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis |
title_fullStr |
Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis |
title_full_unstemmed |
Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis |
title_sort |
dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis |
publisher |
SAGE Publishing |
series |
Therapeutic Advances in Medical Oncology |
issn |
1758-8359 |
publishDate |
2020-07-01 |
description |
Background: Regorafenib (REG) is an oral multikinase inhibitor used in colorectal cancer, gastrointestinal stromal tumour and hepatocellular carcinoma. Several adverse events (AEs) are commonly reported during REG administration, and strategies for managing AEs in everyday clinical practice include supportive care, dose modifications and, when necessary, treatment withdrawal. We performed a systematic review and meta-analysis to assess the schedule treatment modifications of REG associated with AEs across randomized controlled clinical trials (RCTs). Methods: Eligible studies included RCTs assessing standard dose REG versus placebo. Outcomes of interest included: AE-related permanent discontinuation, dose interruptions and dose reductions. Results: We retrieved all the relevant RCTs through PubMed/Med, Cochrane library and EMBASE: 7 eligible studies involving a total of 2099 patients (Regorafenib: 1362; placebo: 737) were included in our analysis. The use of REG was associated with higher incidence and risk of all outcomes of interest when compared with placebo. The incidences of permanent discontinuation, dose interruptions and dose reductions in patients receiving REG were 9.7%, 57.2% and 47%, respectively, versus 3.3%, 16.7% and 7.7% of placebo group; compared with placebo, the summary relative risks (RRs) of permanent discontinuation, dose interruptions and dose reductions in REG arm were 2.80 (95% CI 1.85–4.22), 3.21 (95% CI 2.59–3.99) and 6.02 (95% CI 3.28–11.03), respectively. Conclusions: Treatment with REG at the standard dose of 160 mg is associated with a significant increase in AE-related permanent discontinuation, dose interruptions and dose reductions. Prompt identification and management of AEs seem mandatory to obtain maximal benefit from REG treatment. In the current landscape, dose personalization of REG may have the potential to improve quality of life, minimize treatment discontinuation and maximize patient outcomes. |
url |
https://doi.org/10.1177/1758835920936932 |
work_keys_str_mv |
AT alessandrorizzo dosereductionanddiscontinuationofstandarddoseregorafenibassociatedwithadversedrugeventsincancerpatientsasystematicreviewandmetaanalysis AT margheritanannini dosereductionanddiscontinuationofstandarddoseregorafenibassociatedwithadversedrugeventsincancerpatientsasystematicreviewandmetaanalysis AT marconovelli dosereductionanddiscontinuationofstandarddoseregorafenibassociatedwithadversedrugeventsincancerpatientsasystematicreviewandmetaanalysis AT angeladaliaricci dosereductionanddiscontinuationofstandarddoseregorafenibassociatedwithadversedrugeventsincancerpatientsasystematicreviewandmetaanalysis AT valeriodiscioscio dosereductionanddiscontinuationofstandarddoseregorafenibassociatedwithadversedrugeventsincancerpatientsasystematicreviewandmetaanalysis AT mariaabbondanzapantaleo dosereductionanddiscontinuationofstandarddoseregorafenibassociatedwithadversedrugeventsincancerpatientsasystematicreviewandmetaanalysis |
_version_ |
1724774347593220096 |